Literature DB >> 6335048

Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia.

S Pittman, D Catovsky.   

Abstract

Lymphocytes from 33 out of 63 patients with B-cell chronic lymphocytic leukaemia (B-CLL) were successfully stimulated for cytogenetic analysis by means of two B-cell mitogens: pokeweed mitogen and lipopolysaccharide-B, used after pretreatment of the cells with neuraminidase and galactose oxidase. All patients had abnormal clones in 30-100% of the cells analysed. Chromosomes more frequently involved were Nos. 1, 3, 6, 11, 12, 13 and 14. The most common abnormality was a marker 14q+ (breakpoint 14q32) seen in 17 cases; trisomy 12 was observed in seven cases. A clinical scoring system was used to investigate the correlation of chromosome abnormalities with prognosis. The group with 14q+ was often associated with features of progressive disease, namely; prolymphocytoid or Richter transformation, refractoriness to therapy, high WBC and advanced staging. A significant difference in survival was observed between patients with 14q+ and the rest: median survival from diagnosis being 45 months and over 64 months, respectively (P less than 0.05); when survival was calculated from the time of chromosome analysis the values were 8 months and more than 41 months, respectively (P less than 0.01). It is suggested that 14q+ is acquired during the evolution of CLL and that this development may be a key event in the clinical progression of B-CLL. Other abnormalities, including trisomy 12, were not found to be associated with a worse prognosis.

Entities:  

Mesh:

Year:  1984        PMID: 6335048     DOI: 10.1111/j.1365-2141.1984.tb06112.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

2.  neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation.

Authors:  J G Flanagan; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan Burger; Stefan Faderl; Francesco Paolo Tambaro; Nitin Jain; William G Wierda
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

4.  Lymphocyte-specific protein 1: a specific marker of human leucocytes.

Authors:  K Pulford; M Jones; A H Banham; E Haralambieva; D Y Mason
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 5.  What is the best frontline therapy for patients with CLL and 17p deletion?

Authors:  Xavier C Badoux; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

6.  Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34.

Authors:  M Lafage-Pochitaloff; R Costello; D Couez; J Simonetti; P Mannoni; C Mawas; D Olive
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

7.  Cytogenetic markers in hematoproliferative disorders.

Authors:  C Fonatsch
Journal:  Blut       Date:  1985-11

8.  Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia.

Authors:  T W McKeithan; J D Rowley; T B Shows; M O Diaz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey.

Authors:  Ümmet Abur; Gönül Oğur; Ömer Salih Akar; Engin Altundağ; Huri Sema Aymelek; Düzgün Özatlı; Mehmet Turgut
Journal:  Turk J Haematol       Date:  2017-11-13       Impact factor: 1.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.